Therapy area review
PIPELINE BY THERAPY AREA
This section contains further information about the therapy areas on which our efforts are focused: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. We describe the business environment, trends and other factors that have influenced our decision to focus on diseases in these six areas, our strategic objectives for each and our progress towards achieving these objectives. We include information about our marketed medicines and how they are designed to make a meaningful difference for patients, together with an overview of performance during the year. We also report in detail on the potential new products and product life-cycle developments in our pipeline that reflect our commitment to maintaining a flow of innovation that adds value for our shareholders and society.
Detailed information about relevant continuing litigation can be found in Note 25 to the Financial Statements.
SALES BY THERAPY AREA ($ MILLION)
1 Includes Synagis and FluMist which were acquired in June 2007.
